Melanocortin Neuropeptides & Ethanol Intake
黑皮质素神经肽
基本信息
- 批准号:6985128
- 负责人:
- 金额:$ 26.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-08-01 至 2009-06-30
- 项目状态:已结题
- 来源:
- 关键词:alcoholic beverage consumptionautoradiographybehavior testbehavioral /social science research tagbiological signal transductionethanolgenetically modified animalshormone inhibitorhormone receptorhormone regulation /control mechanismimmunocytochemistrylaboratory mousemelanocyte stimulating hormoneneurobiologyneurotransmitter antagonistproopiomelanocortinreceptor expressionself medicationsubstance abuse related behavior
项目摘要
DESCRIPTION (provided by applicant): Endogenous opioid peptides, including proopiomelanocortin (POMC)-derived beta-endorphin, modulate neurobiological responses to ethanol and administration of ethanol alters the expression of POMC and beta- endorphin. Given that ethanol has direct effects on POMC activity, it is possible that the other POMC-derived peptides, namely the melanocortins (MCs), are also involved with neurobiological responses to ethanol. MC peptides include alpha-melanocyte stimulating hormone (alpha-MSH), which is synthesized in the arcuate nucleus of the hypothalamus, the nucleus of the solitary tract, and the medulla, regions that project to many brain regions of known relevance to alcoholism. Pre-treatment with MC receptor (MCR) agonists reduce heroin self-administration and chronic administration of morphine or cocaine increases MC-4 receptor (MC4R) levels in striatum rats. Interestingly, rats selectively bred for high ethanol consumption have abnormal levels of MC-3 receptor (MC3R) and MC4R in the nucleus accumbens (NAc) and hypothalamus, and we have provided preliminary findings indicating that intracerebroventricular (i.c.v.) infusion of a selective MC4R agonist reduces, while i.c.v. infusion of a non-selective MCR antagonist increases, ethanol drinking by C57BL/6J mice. Hence, the specific aims proposed below will test the guiding hypothesis that MCR signaling modulates ethanol consumption and neurobiological responses to ethanol. Specifically, we will determine if MC3R and/or MC4R signaling limits self-administration of ethanol by mice (Specific Aim 1), if the endogenous MCR antagonist, agouti-related protein (AgRP), promotes ethanol self-administration by mice (Specific Aim 2), if MCR agonists and antagonists influence ethanol consumption by acting on the MC3R and/or MC4R (Specific Aim 3), and if administration of ethanol will increase alpha-MSH and MC3R/MC4R levels while at the same time decrease AgRP levels, a response that could theoretically protect against uncontrolled ethanol drinking (Specific Aim 4).
描述(由申请人提供):内源性阿片肽,包括原黑素皮质素(POMC)衍生的-内啡肽,调节对乙醇的神经生物学反应,乙醇管理改变POMC和-内啡肽的表达。鉴于乙醇对POMC活性有直接影响,其他POMC衍生肽,即黑素皮质素(MCs)也可能参与对乙醇的神经生物学反应。MC肽包括α -黑素细胞刺激激素(α - msh),它在下丘脑弓状核、孤立束核和延髓中合成,这些区域投射到许多已知与酒精中毒相关的大脑区域。纹状体大鼠MC-4受体(MCR)激动剂预处理可减少海洛因自我给药,而长期给药吗啡或可卡因可增加MC-4受体(MC4R)水平。有趣的是,选择性饲养的高乙醇消耗大鼠在伏隔核(NAc)和下丘脑中有异常水平的MC-3受体(MC3R)和MC4R,我们提供的初步研究结果表明,C57BL/6J小鼠的乙醇饮用性,脑室内(i.c.v.)输注选择性MC4R激动剂减少,而i.c.v.输注非选择性MCR拮抗剂增加。因此,下面提出的具体目标将检验MCR信号调节乙醇消耗和对乙醇的神经生物学反应的指导假设。具体来说,我们将确定MC3R和/或MC4R信号是否限制小鼠对乙醇的自我给药(特异性目标1),内源性MCR拮抗剂,agoutii相关蛋白(AgRP)是否促进小鼠对乙醇的自我给药(特异性目标2),MCR激动剂和拮抗剂是否通过作用于MC3R和/或MC4R来影响乙醇的消耗(特异性目标3),以及给药是否会增加α - msh和MC3R/MC4R水平,同时降低AgRP水平。这种反应理论上可以防止不受控制的乙醇饮用(具体目标4)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TODD E. THIELE其他文献
TODD E. THIELE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TODD E. THIELE', 18)}}的其他基金
Neuropeptide Y: Role in Ethanol Intake and Sensitivity
神经肽 Y:在乙醇摄入和敏感性中的作用
- 批准号:
10608410 - 财政年份:2023
- 资助金额:
$ 26.32万 - 项目类别:
The role of brainstem norepinephrine in binge alcohol drinking and taste aversion
脑干去甲肾上腺素在酗酒和味觉厌恶中的作用
- 批准号:
9883691 - 财政年份:2018
- 资助金额:
$ 26.32万 - 项目类别:
The role of brainstem norepinephrine in binge alcohol drinking and taste aversion
脑干去甲肾上腺素在酗酒和味觉厌恶中的作用
- 批准号:
10658145 - 财政年份:2018
- 资助金额:
$ 26.32万 - 项目类别:
The role of brainstem norepinephrine in binge alcohol drinking and taste aversion
脑干去甲肾上腺素在酗酒和味觉厌恶中的作用
- 批准号:
10357861 - 财政年份:2018
- 资助金额:
$ 26.32万 - 项目类别:
The role of corticotropin releasing factor in binge-like ethanol drinking
促肾上腺皮质激素释放因子在酗酒中的作用
- 批准号:
9274895 - 财政年份:2013
- 资助金额:
$ 26.32万 - 项目类别:
The role of corticotropin releasing factor in binge-like ethanol drinking
促肾上腺皮质激素释放因子在酗酒中的作用
- 批准号:
8459114 - 财政年份:2013
- 资助金额:
$ 26.32万 - 项目类别:
The role of corticotropin releasing factor in binge-like ethanol drinking
促肾上腺皮质激素释放因子在酗酒中的作用
- 批准号:
8700253 - 财政年份:2013
- 资助金额:
$ 26.32万 - 项目类别:
The role of corticotropin releasing factor in binge-like ethanol drinking
促肾上腺皮质激素释放因子在酗酒中的作用
- 批准号:
9061510 - 财政年份:2013
- 资助金额:
$ 26.32万 - 项目类别:
相似海外基金
Harnessing PET to Study the In Vivo Fate and Health Effects of Micro- and Nanoplastics
利用 PET 研究微塑料和纳米塑料的体内命运和健康影响
- 批准号:
10890903 - 财政年份:2023
- 资助金额:
$ 26.32万 - 项目类别:
Altered microglia states and microglia-endothelial cell axis in relation to white matter disease progression in VCID
VCID 中小胶质细胞状态和小胶质细胞内皮细胞轴的改变与白质疾病进展相关
- 批准号:
10738860 - 财政年份:2023
- 资助金额:
$ 26.32万 - 项目类别:
Subtype-Selective Metabotropic Glutamate Receptor PET Ligands
亚型选择性代谢型谷氨酸受体 PET 配体
- 批准号:
10576674 - 财政年份:2023
- 资助金额:
$ 26.32万 - 项目类别:
Circadian Rhythms in Blood Brain Barrier Permeability and Increased Efficacy of Chemotherapy for Brain Metastases
血脑屏障通透性的昼夜节律和脑转移化疗疗效的提高
- 批准号:
10663717 - 财政年份:2023
- 资助金额:
$ 26.32万 - 项目类别:
Glycogen synthase kinase 3 ligand discovery for Alzheimer’s disease
糖原合成酶激酶 3 配体发现治疗阿尔茨海默病
- 批准号:
10637434 - 财政年份:2023
- 资助金额:
$ 26.32万 - 项目类别:
Assessing Diffusion MRI Metrics for Detecting Changes of Synaptic Density in Alzheimer's Disease
评估弥散 MRI 指标以检测阿尔茨海默病突触密度的变化
- 批准号:
10739911 - 财政年份:2023
- 资助金额:
$ 26.32万 - 项目类别:
Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers
支持在吸烟者 2 期临床研究中评估 mGlu2 PAM SBP-9330 的安全性/毒理学、ADME 和 CMC 活动
- 批准号:
10829189 - 财政年份:2023
- 资助金额:
$ 26.32万 - 项目类别:
Probing D2 and 5HT-2A mechanisms in early visual processing in V1
探索 V1 早期视觉处理中的 D2 和 5HT-2A 机制
- 批准号:
10605769 - 财政年份:2023
- 资助金额:
$ 26.32万 - 项目类别:
Develop in vivo PET imaging probes for ROCK2 as a biomarker of early Alzheimer's disease.
开发 ROCK2 的体内 PET 成像探针作为早期阿尔茨海默病的生物标志物。
- 批准号:
489145 - 财政年份:2023
- 资助金额:
$ 26.32万 - 项目类别:
Operating Grants














{{item.name}}会员




